Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
REC board to consider raising up to Rs 70,000 cr via NCDs

2018-07-18 moneycontrol
Rural Electrification Corporation (REC) on Tuesday said its board will consider a proposal this month to raise up to Rs 70,000 crore through issuance of non-convertible debentures on private placement basis.
532955 RECLTD

0
Adani Transmission rises 3% on LoI for transmission project in Uttar Pradesh

2018-06-14 moneycontrol
Shares of Adani Transmission rose more than 3 percent in the opening trade on Thursday as company received LoI intra state transmission project in Uttar Pradesh.
539254 532955 RECLTD ADANITRANS

0
REC commits $1 mn to International Solar Alliance

2018-06-04 moneycontrol
State-run power sector financier Rural Electrification Corporation (REC) today announced its commitment of USD 1 million to International Solar Alliance (ISA). "In view of the World Environment Day 2018, REC contributed USD one million to the International Solar Alliance (ISA) becoming a corpus contributor," an REC statement said.
532955 RECLTD

21
Market Live: Sensex dips 200 pts amid weak rupee; MM rallies on Q4 earnings

2018-05-29 moneycontrol
Earnings Reaction: Godfrey Phillips India's March quarter profit dropped 22.8 percent year-on-year to Rs 43.1 crore and revenue from operations declined 37.6 percent to Rs 543.3 crore.
500325 RELIANCE 532955 532712 STAR RCOM RIGD GODFRYPHLP HDFCBANK RLNIY BANKINDIA IBN 538835 DCMSRMIND 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 BRHTY INTELLECT 500103 RECLTD 500163 523369 MANPASAND

23
Market Live: Sensex falls 100 pts, rupee slips 50 paise; BHEL up 9% on Q4 nos

2018-05-29 moneycontrol
Earnings: M&M's March quarter earnings beat analyst expectations as profit grew by 50 percent year-on-year to Rs 1,155 crore and revenue increased 25.6 percent to Rs 13,189 crore during the quarter.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD HDFCBANK RLNIY BANKINDIA 524804 IBN 538835 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 ARBQY BRHTY INTELLECT 500103 RECLTD MANPASAND

23
Market Live: Sensex rangebound, PSU Bank index loses 2%; BHEL up 9% on Q4 nos

2018-05-29 moneycontrol
Market Update: Benchmark indices as well as broader markets are in a consolidation mode after sharp rally seen in previous three consecutive sessions. Investors closely monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 538835 BHEL 539207 532531 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 BRHTY INTELLECT 500103 RECLTD MANPASAND ADFFOODS

20
Market Live: Nifty reclaims 10,700 amid weaker rupee; Vista Pharma up 10%

2018-05-29 moneycontrol
Market Update: The market continued to consolidate after rallying sharply in previous three consecutive sessions. Investors keenly monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 539207 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 RECLTD MANPASAND ADFFOODS

10
Market Live: Sensex, Nifty consolidate after 3-day rally; weaker rupee lifts IT stocks

2018-05-29 moneycontrol
Buzzing: After being locked in lower circuit on Monday, shares of Manpasand Beverages continued to be locked in the same band today as well, as investors continued to be wary of corporate developments. This is despite the company trying to allay fears around the controversy surrounding its auditor, Deloitte, resigning abruptly.
IPCALAB AUROPHARMA 524804 532955 532712 539207 533106 RCOM 524494 OIL HDB 500180 ARBQY 519183 526797 GREENPLY HDFCBANK RECLTD MANPASAND ADFFOODS

0
REC Q4 net profit down 37% on higher provisions

2018-05-28 moneycontrol
Rural Electrification Corporation (REC) on Monday reported a 37 percent decrease YOY in its March quarter net profit at Rs 834.79 crore, missing estimates due to an increase in provisions for bad loans.
532955 RECLTD

7
ICICI-led group to sell Essar Power arm to recover dues

2018-05-27 freepressjournal.in
Mumbai : An ICICI Bank-led consortium, which includes Rural Electrification Corp, Power Finance Corp, Punjab National Bank and IDFC, is looking to sell Essar Power MP, to recover Rs 6,600 crore of dues, sources said.
PFC PWQFY ICICIBANK PNJZY 532461 532174 IBN PNB 532955 RECLTD 532810

10
4 years of Modi govt, but no achche din for PSU stocks

2018-05-25 thehindubusinessline
Under four years of Modi government, public sector companies, led by banks, have suffered the most. The Nifty PSU Bank index is undoubtedly the biggest loser with negative returns of 24 per cent over the last four years, thanks to lack of meaningful resolution of non-performing assets (NPAs). Analysts have pointed out that the government’s inability to solve the NPA issue has been one of the biggest misses despite the bankruptcy code and recapitalisation.
PWQFY 532955 532810 533278 BHEL PFC 533106 OIL GAILY BRHTY 500103 GAILF RECLTD CLNDY COALINDIA

46
World’s Largest ID Database Exposed by Indian Government Errors - Bloomberg

2018-05-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BC94 SMSN MSFT 532955 RECLTD SMSD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...